

IN THE CLAIMS:

The following Listing of Claims replaces all prior Listings, and versions, of claims in the above-identified patent application.

Listing of Claims

What is claimed is:

1-7. (Cancelled)

8. (Currently Amended) An isolated antibody, antigen binding fragment, or binding partner, that selectively binds to a protein of ~~Claim 1~~ selected from the group consisting of:

a. a protein consisting essentially of an amino acid sequence selected from the group consisting of:

i. an amino acid sequence spanning from between about positions 252 and 289 of SEQ ID NO:3 to about position 414 of SEQ ID NO:3;

ii. an amino acid sequence spanning from between about positions 252 and 289 of SEQ ID NO:5 to about position 403 of SEQ ID NO:5;

iii. an amino acid sequence spanning from between about positions 206 and 243 of SEQ ID NO:7 to about position 349 of SEQ ID NO:7; and,

iv. an amino acid sequence spanning from between about positions 257 and 294 of SEQ ID NO:9 to about position 408 of SEQ ID NO:9; and,

b. a homologue of the protein of (a), wherein said homologue consists essentially of an amino acid sequence that is at least about 70% identical to said amino acid sequence of (a);

wherein said isolated phosphatidylserine receptor protein has a phosphatidylserine receptor biological activity.



9. (Currently Amended) The isolated antibody, antigen binding fragment, or binding partner of Claim 8, wherein said antibody selectively binds to a protein consisting essentially of a fragment of SEQ ID NO:3 spanning from between about positions 252 and 289 of SEQ ID NO:3 and about position 414 of SEQ ID NO:3.

10. (Currently Amended) The isolated antibody, antigen binding fragment, or binding partner of Claim 8, wherein said antibody selectively binds to a protein consisting essentially of a fragment of SEQ ID NO:5 spanning from between about positions 252 and 289 of SEQ ID NO:5 and about position 403 of SEQ ID NO:5.

11-36. (Cancelled)

37. (Currently Amended) An isolated antibody, antigen binding fragment, or binding partner, that selectively binds to the protein of ~~Claim 24~~ selected from the group consisting of:

a. a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9; and,

b. a homologue of the protein of (a), wherein said homologue comprises an amino acid sequence that is at least 316 amino acid residues in length and that is at least about 70% identical to said amino acid sequence of (a), wherein said homologue is not SEQ ID NO:3;

wherein said isolated phosphatidylserine receptor protein has a phosphatidylserine receptor biological activity.

38. (Currently Amended) The isolated antibody, antigen binding fragment, or binding partner of Claim 37, wherein said antibody selectively binds to a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9.

39-64. (Cancelled)

65. (Original) A method to stimulate or increase the activity of a phosphatidylserine receptor, comprising contacting a phosphatidylserine receptor with an agonist of said phosphatidylserine receptor, wherein said agonist increases the activity of said phosphatidylserine receptor, and wherein said receptor comprises an amino acid sequence



selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9.

66. (Currently Amended) The method of Claim 65, wherein said agonist is selected from the group consisting of: an antibody that selectively binds to and activates said phosphatidylserine receptor, an antigen binding fragment that selectively binds to and activates said phosphatidylserine receptor, and a binding partner that selectively binds to and activates said phosphatidylserine receptor, ~~phosphatidylserine, and a product of drug design that increases the activity of said receptor as compared to in the absence of said product.~~

67-74. (Cancelled)

75. (Original) A method to reduce the activity of a phosphatidylserine receptor, comprising contacting a phosphatidylserine receptor with an antagonist of said phosphatidylserine receptor, wherein said antagonist decreases the activity of said phosphatidylserine receptor, and wherein said receptor comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:9.

76. (Currently amended) The method of Claim 75, wherein said antagonist is selected from the group consisting of an antibody that reduces the activity of said receptor, an antigen binding fragment that reduces the activity of said receptor, and a binding partner that reduces the activity of said receptor, ~~a product of drug design that reduces the biological activity of said receptor, an anti-sense nucleic acid molecule that binds to a nucleic acid molecule encoding the receptor, a ribozyme that is specific for PS receptor RNA, and a soluble phosphatidylserine receptor.~~

77. (Original) The method of Claim 75, wherein said antagonist is an antibody that selectively binds to said receptor and reduces the activity of said receptor.

78-87. (Cancelled)